<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999284</url>
  </required_header>
  <id_info>
    <org_study_id>96048</org_study_id>
    <nct_id>NCT00999284</nct_id>
  </id_info>
  <brief_title>Ophthalmologic Examinations After Infusion of ZK200775</brief_title>
  <official_title>Ophthalmologic Examinations After 4-hour Infusion of ZK200775 in Healthy Elder Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ZK 200775 is an antagonist at the α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)&#xD;
      receptor and had earned attention a possible neuroprotective agent in cerebral ischemia.&#xD;
      Probands receiving the agent within a stroke therapy related Phase I trial reported on an&#xD;
      alteration of visual perception. In this trial, the effects of ZK 200775 on the visual system&#xD;
      will be analyzed in detail.&#xD;
&#xD;
      In a randomised, placebo-controlled, double-blind study eyes and vision will be examined&#xD;
      before and after the intravenous administration of ZK 200775. The following methods will be&#xD;
      applied: clinical examination, visual acuity, ophthalmoscopy, colour vision, rod absolute&#xD;
      threshold, central visual field, pattern-reversal visual evoked potentials (pVEP), ON-OFF and&#xD;
      full-field electroretinogram (ERG).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1996</start_date>
  <completion_date type="Actual">April 1998</completion_date>
  <primary_completion_date type="Actual">April 1998</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Color vision (Panel D-15 test), dark vision (adaptometer), full-field electroretinogram</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Visual Acuity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham infusion of sodium chloride 0.9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of 0.3 mg/kg/h ZK200775 over 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of 0.75 mg/kg/h ZK200775 over 4 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZK200775</intervention_name>
    <description>Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.</description>
    <arm_group_label>Low dose arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZK200775</intervention_name>
    <description>Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.</description>
    <arm_group_label>High dose arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride</intervention_name>
    <description>Intravenous infusion of sodium chloride over a period of 4 hours.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant must be a voluntary proband&#xD;
&#xD;
          -  Age between 55 and 65 years&#xD;
&#xD;
          -  Body weight must not exceed the following value: Body height in cm minus 100 = body&#xD;
             weight [kg] +/- 20%&#xD;
&#xD;
          -  Male sex&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Physical examination: Probands must show normal findings without clinical relevance,&#xD;
             mental and physical health is required;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical history:&#xD;
&#xD;
               -  Substantial pre-existing medical condition&#xD;
&#xD;
               -  Known allergy to the employed effective components or galenic components&#xD;
&#xD;
          -  Medicaments and drugs&#xD;
&#xD;
               -  Intake of systemically or locally acting drugs which conflict with the aim of the&#xD;
                  trial or that can influence the results (antipsychotic drugs, antidepressants,&#xD;
                  barbiturates and benzodiazepines)&#xD;
&#xD;
               -  A clinical history that hints to substance or alcohol abuse&#xD;
&#xD;
               -  Nicotine abuse of more than 10 cigarettes a day&#xD;
&#xD;
               -  Consumption of alcoholic beverages on the day prior to the examinations&#xD;
&#xD;
               -  Extreme physical stress (sports or work) within 8 days prior to the examinations&#xD;
&#xD;
               -  Blood donation within 2 months prior to the examinations&#xD;
&#xD;
               -  Relevant vaccination or stay abroad&#xD;
&#xD;
               -  Special or onesided alimentation (strict vegetarianism, low-caloric diet)&#xD;
&#xD;
               -  Simultaneous participation in another clinical trial&#xD;
&#xD;
          -  Vital signs (after 3 minutes of rest)&#xD;
&#xD;
               -  Blood pressure with systolic values &gt; 160 mmHg and / or diastolic values &gt; 95&#xD;
                  mmHg&#xD;
&#xD;
               -  Heart frequency: Values beyond 50-100 beats per minute&#xD;
&#xD;
          -  Electrocardiogram&#xD;
&#xD;
               -  abnormal 12-channel ECG&#xD;
&#xD;
          -  Laboratory findings&#xD;
&#xD;
               -  Hepatitis antigen (HBsAG), hepatitis C-antibodies or positive HIV-test&#xD;
&#xD;
          -  Clinical pharmacology&#xD;
&#xD;
               -  positive drug test&#xD;
&#xD;
               -  clinically relevant abnormalities of the examined parameters&#xD;
&#xD;
          -  Opinion of the investigator: when due to scientific or personal reasons or matters of&#xD;
             compliance or safety a patient should not take part in the trial&#xD;
&#xD;
          -  Opacification of optic media, retinal disease, optic nerve disease, amblyopia or color&#xD;
             vision defects&#xD;
&#xD;
          -  Status post intraocular surgery (exception: cataract surgery with implantation of a&#xD;
             posterior chamber lens), laser coagulation&#xD;
&#xD;
          -  Myopia &gt; -5 diopters, hyperopia &gt; +5 diopters&#xD;
&#xD;
          -  Narrow angle glaucoma&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Staks, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Unviversitätsmedizin Berlin, Augenklinik Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>October 20, 2009</study_first_submitted>
  <study_first_submitted_qc>October 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2009</study_first_posted>
  <last_update_submitted>October 20, 2009</last_update_submitted>
  <last_update_submitted_qc>October 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Thomas Staks</name_title>
    <organization>Bayer Schering Pharma AG</organization>
  </responsible_party>
  <keyword>ZK200775 is tested for its effects on vision on healthy probands.</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

